Lorient Capital
Lorient Capital focuses exclusively on healthcare and publicly describes majority and control investments, founder buyouts, executive partnerships, and embedded operating support.
What stands out about Lorient Capital
Lorient Capital targets healthcare providers, services, and technology companies, generally seeking $5–25M EBITDA at entry, significant seller rollover, and majority or control ownership structures.[1][3][4][5][6][7]
What does Lorient Capital invest in?
Lorient Capital is a private investment firm focused exclusively on healthcare. Its stated model provides control-oriented private equity capital to healthcare providers, services, and technology companies through founder buyouts and executive partnerships.
Lorient also describes embedded operating support through L1OS, its operating system, and Morpheus, its data platform. The firm’s official Fund III announcement states that it had completed 20 platform investments, over 75 add-on acquisitions, and nine realized exits since inception.[1][3][4][5]
Lorient describes two core strategies. Founder buyouts involve acquiring founder-led businesses, while executive partnerships involve partnering with experienced executives to build companies from the ground up.
The firm states that it generally targets majority and control ownership structures and provides $25-$100M of equity per platform. Its operating model includes L1OS, which it describes as providing shared performance definitions, planning and execution cadence, accountability, integration and expansion sequencing, and embedded operating support.[3]
Owners evaluating a financial buyer can compare the offer with independent valuation analysis, understand how acquirers approach transactions through Auxo’s buy-side M&A process guide, and consider whether a full or partial sale best fits their objectives.
Published criteria: Lorient states that its target business profile includes $5–25M EBITDA at entry, first institutional capital, 20%+ top-line growth or clear levers to accelerate, meaningful margin expansion opportunity, significant seller rollover, and leadership teams seeking embedded operating support. It states that it provides $25-$100M of equity per platform and targets majority and control ownership structures.[3][4]
What should a business owner evaluate before considering a transaction with Lorient Capital?
Owners evaluating Lorient should clarify the ownership percentage and governance rights sought, the expected seller-rollover percentage and terms, and the treatment of valuation, earnouts, debt, and management incentive pools. They should also ask how L1OS and Morpheus resources would be used, how much autonomy existing management would retain, and what add-on acquisition capabilities and capital commitments would be available.
The official Our Model page does not state an expected investment holding period or exit timing, so owners should request Lorient’s investment horizon and exit approach directly. References from founders who completed comparable founder-buyout or executive-partnership transactions may also be requested.[3][5]
What seller-rollover percentage is expected, and on what terms
How are valuation, rollover equity, earnouts, debt, and management incentive pools structured
What companies does Lorient Capital target?
Lorient states that its target business profile includes $5–25M EBITDA at entry, first institutional capital, 20%+ top-line growth or clear levers to accelerate, meaningful margin expansion opportunity, significant seller rollover, and leadership teams seeking embedded operating support.
These criteria are stated alongside a majority and control ownership orientation and $25-$100M of equity per platform.[3]
Lorient targets healthcare providers, healthcare services, and healthcare technology companies. Its identified focus areas include consumer-directed healthcare, post-acute care, behavioral health, provider enablement, and tech-enabled services.[4]
Lorient states that its investments support the U.S. healthcare system. It lists offices in Miami, Florida; Birmingham, Michigan; and New York City.[1][2]
Lorient publicly distinguishes platform investments from add-on acquisitions in reporting its investment activity. Its Fund III announcement states that, since inception, it had completed 20 platform investments and over 75 add-on acquisitions.
Lorient’s official portfolio page identifies current and realized portfolio companies but does not publish company-by-company investment dates, entry valuation, consideration, ownership percentage, or exit proceeds.[4][6]
Lorient’s official portfolio identifies current investments including American Family Care, Manor, Midwest Express Clinic, Pelvic Rehabilitation Medicine, PeterMD, Primor Health, PurposeCare, Reveal Dental Partners, ShiftKey, Transitions Care, and Vitae Health Systems. It identifies realized investments including Behavior Frontiers, Centria Healthcare, ClearGage, Elite Patient Care, Healthy Living Network, MedCerts, The CORE Institute, and Vet’s Best Friend.[6]
On May 12, 2026, Lorient announced a majority equity investment in PeterMD in conjunction with Emanate. On May 5, 2025, Lorient announced that Behavior Frontiers was sold to NexPhase Capital following Lorient’s investment and operational partnership with the company.
Other official announcements include American Family Care’s partnership with Lorient Capital on March 5, 2024; Rise Health’s launch with a growth equity investment made by Lorient and Martis Capital on December 19, 2022; and PurposeCare’s launch after the acquisition of Indiana-based Purpose Home Health, with Lorient Capital identified as an investment partner.[1][7][8][9][10]
What is not clear from Lorient Capital's public investment criteria?
The official Our Model page specifies entry criteria, equity per platform, and majority/control ownership structures but does not state an expected investment holding period or exit timing.
The official portfolio page identifies current and realized portfolio companies but does not publish company-by-company investment dates, entry valuation, consideration, ownership percentage, or exit proceeds. The PeterMD transaction announcement identifies the majority equity investment and participating parties but does not disclose transaction value, purchase price, or ownership percentage.[3][6][7]
Questions to ask when evaluating Lorient Capital as a buyer or investment partner
What ownership percentage and governance rights does Lorient typically seek?
What seller-rollover percentage is expected, and on what terms?
How are valuation, rollover equity, earnouts, debt, and management incentive pools structured?
Which L1OS and Morpheus implementation resources would be assigned to the company, and for how long?
What is the expected investment horizon and exit approach?
How much autonomy would existing management retain?
Which add-on acquisition capabilities and capital commitments would be available?
What are the firm’s references from founders who completed similar founder-buyout or executive-partnership transactions?
Sources & research notes
- Official website / firm overview
- Geography / market coverage
- Investment strategy
- Industry / market focus
- Investment approach
- Transaction / portfolio evidence
- Transaction / portfolio evidence
- Transaction / portfolio evidence
- Transaction / portfolio evidence
- Transaction / portfolio evidence
- SEC filing / regulatory record
- Structure / regulatory context
- Public Process
How this profile was researched
Auxo profiles are prepared from publicly available primary and authoritative sources and reviewed for entity identity, factual support and disclosure consistency. When a fact cannot be supported by the reviewed public record, the profile identifies it as something to confirm directly rather than inferring it.
Independent research profile
This profile was prepared by Auxo Capital Advisors from publicly available information believed to be reliable and is provided solely for informational and educational purposes. It is not an endorsement, recommendation, ranking, solicitation, or representation regarding the profiled firm, its services, qualifications, transaction experience, regulatory status, financial condition, or suitability for any particular person, company, transaction, or investment.
Information obtained from third-party and public sources may be incomplete, inaccurate, outdated, or subject to change, and Auxo Capital Advisors makes no representation or warranty, express or implied, as to its accuracy, completeness, or timeliness. Readers should conduct their own independent diligence and consult appropriate professional advisers before engaging any advisor, intermediary, investor, lender, acquirer, or other transaction counterparty.
Broker-dealer and securities disclosure
Auxo Capital Advisors is an affiliate of Weild & Co., Member FINRA | SIPC. Securities-related activities and securities transactions are conducted through Weild & Co.
Nothing contained on this page constitutes an offer to sell, an offer to purchase, or a solicitation of an offer to buy or sell any security, investment product, or financial instrument. Nothing on this page constitutes investment advice, a recommendation regarding any security, or a recommendation to enter into any transaction with the profiled firm or any other party.
Any securities transaction, capital-raising engagement, investment-banking engagement, or other securities-related activity involving Auxo Capital Advisors or Weild & Co. is subject to applicable regulatory requirements, internal review and approval, suitability and other applicable diligence requirements, and the terms of a separate written engagement or transaction agreement, as applicable.
Inclusion of a third-party firm in this directory does not imply affiliation with, sponsorship by, endorsement by, or any other relationship with Auxo Capital Advisors or Weild & Co. unless expressly stated otherwise.